Comparison of the European and U.S. guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.

Both 2022 USPSTF and 2021 ESC guidelines particularly reduced lipid-lowering therapy eligibility in women. Nearly half of women who faced an incident ASCVD were not eligible for lipid-lowering therapy.